← boardnext 2027-10
DARE
Daré Bioscience, Inc.distress 5/10 · elevated risk$1.24+2%today-62% from 52w high
Lead: Human Papilloma Virus (HPV)
Revenue
pre-revenue
Liquidity
$19M
Runway
1.9 yrs
Shares 1y
+11%
Price & events
-37.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.6%
1D
-36.1%
1W
-40.1%
1M
-41.5%
3M
-36.4%
6M
-53.4%
1Y
-65.9%
2Y
-93.1%
5Y
-92.1%
All
Overview
- Market Cap
- $18.57M
- Volume
- 23.08K
- 52 Week Range
- $1.22 – $3.27
- Total Shares
- 14.98M
- Float Shares
- 13.73M
- Short %
- 4.64%
- % Held by Insiders
- 8.55%
- % Held by Institutions
- 8.42%
- RVOL
- 0.13x
- Beta
- 1.02
Pipeline stages · 1 programs
Lopinavir / ritonavir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-10 Estimated 50% readout ~2027-11-15 | Phase 2 | Lopinavir / ritonavir | Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection | — | not yet recruiting |
Catalyst news & presentations · 5
- 2026Guided 40%enrollment completesecondaryPhase 3Ovaprene · Enrollment completion anticipated in 2026SEC 8-K
- 2026-08-13Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-11-26withdrawalOvaprene · Bayer terminated license agreement effective Feb 24, 2026 due to strategic prioritizationSEC 8-K
- 2024-10-23partnershipDARE-HPV · Selected for ARPA-H Sprint for Women's Health, subaward up to $10M for development.SEC 8-K
- 2024-10-21partnershipEntered purchase agreement with Lincoln Park Capital for up to $15M in common stock sales over 24 months.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-12-02HC Wainwright & Co.Buy
- 2025-09-04Maxim GroupHold → Buy
- 2025-04-01HC Wainwright & Co.Buy
- 2024-12-17HC Wainwright & Co.Buy
- 2024-11-15HC Wainwright & Co.Buy
- 2024-10-24HC Wainwright & Co.Buy
Competitors — Human Papilloma Virus (HPV)
- none identified
Recent news
- 2026-07-21Daré Bioscience, Inc. (NASDAQ:DARE): Are Analysts Optimistic? - Sahm
- 2026-07-17Dare Bioscience Received Notice of Delisting - TradingView
- 2026-07-08Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
- 2026-07-06DARE Q1 2026 Earnings: Narrower-Than-Expected Loss Lifts Sentiment Amid Pre-Revenue Phase - Earnings Beat Streak - dars.gov.et
- 2026-07-05Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
- 2026-07-02Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees - Stock Titan
- 2026-07-02Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
- 2026-07-02Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.